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Pathogenesis and available interventions
Multiple sclerosis (MS) is a heterogeneous disease with
multiple neuropathological subtypes, and a variable ge-
netic background that impacts on immune reactivity
and the vulnerability and repair capacity of central ner-
vous system (CNS) tissue. Furthermore, the role of au-
toimmunity/inflammation is complex, and may change
over time and in different disease courses. There is also
increasing evidence that a progressive neurodegenera-
tive process takes place, which is only loosely (if at all)
associated with the autoimmune attack, especially later
in the disease evolution.
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■ Abstract Disease-modifying
treatments (DMTs) for multiple
sclerosis (MS) are now widely
available, and their beneficial ef-
fects on relapse rates, magnetic res-
onance imaging outcomes and, in
some cases, relapse-related disabil-
ity have been shown in numerous
clinical studies. However, as these
treatments are only partially effec-
tive in halting the MS disease
process, the search for improved
treatment regimens and novel ther-
apies must continue. Strategies to
improve our therapeutic armamen-
tarium have to take into account
the different phases or parts of the
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pathogenesis of the disease. Avail-
able treatments address systemic
immune dysfunction, blood-brain
barrier permeability and the in-
flammatory process in the central
nervous system. Currently, patients
who fail to respond adequately to
first-line DMTs are often consid-
ered as candidates for intensive im-
munosuppression with cytostatic
agents or even autologous stem cell
transplantation. However, new ap-
proaches are being developed.
Combination therapies offer an al-
ternative approach that may have
considerable potential to improve
therapeutic yield and, although
likely to present considerable chal-
lenges in terms of trial design, this
certainly seems to be a logical step
forward in view of the complex
pathology of MS. Several new
drugs are also being developed
with the aim of providing more ef-
fective, convenient and/or specific
modulation of the inflammatory
component of the disease. These
treatments include humanised
monoclonal antibodies such as the
anti-VLA-4 antibody natalizumab,
inhibitors of intracellular activa-
tion, signalling pathways and T-cell
proliferation, and oral immuno-
modulators such as sirolimus,
teriflunomide or statins. There re-
mains, however, an urgent need for
treatments that protect against de-
myelination and axonal loss, or
promote remyelination/regenera-
tion. Due to the chronicity of MS,
the therapeutic window for neuro-
protective agents is wider than that
following stroke or acute spinal
cord injury, and may therefore al-
low the use of some drugs that
have proven disappointing in other
situations. Novel potential neuro-
protective agents such as α-amino-
3-hydroxy-5-methyl-4-isoxa-
zolepropionic acid antagonists and
ion-channel blockers will be enter-
ing Phase II trials in MS in the near
future, and it is hoped that these
agents will mark the start of a new
era for DMTs for MS.
■ Key words multiple sclerosis ·
immunomodulators · monoclonal
antibodies · neuroprotection
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Three mechanisms of tissue injury – immunological,
excitotoxic and metabolic – have been proposed to be
involved in the pathogenesis of MS, and each of these
represents a group of possible therapeutic targets. Im-
munological factors can be subdivided into antigen-spe-
cific (direct attack on neurons and axons by T-cells and
antibodies) and antigen non-specific (indirect damage
of neurons and axons by inflammatory mediators from
the innate immune system; cytokine-mediated path-
ways of neurotoxicity; and inflammation-related release
of toxic factors such as nitric oxide). Transmitters such
as glutamate cause an influx of excitotoxins, such as cal-
cium or sodium ions, and create free radicals. Metabolic
factors, including mitochondrial dysfunction and ox-
idative or metabolic stress, may also play a role in the
pathogenic process.
Strategies to improve the therapeutic armamentar-
ium also have to take into account the different phases
or mechanism of the pathogenesis of MS. There are
three major components of MS pathogenesis that are
targeted by the currently available therapies – systemic
immune dysfunction, increased permeability of the
blood-brain barrier, and changes in the CNS
parenchyma (Table 1). However, there is now an urgent
need for therapeutics targeted at protecting against de-
myelination and axonal loss, as well as those promoting
remyelination/regeneration.
Disease-modifying treatments
Disease-modifying treatments (DMTs) for MS are now
widely available.Their beneficial effects on relapse rates,
relapse-related disability and magnetic resonance imag-
ing (MRI) measures have been shown in numerous clin-
ical studies [1–8]. These effects, which are more pro-
nounced early in the course of the disease, are
long-lasting and have no rebound effects. Their efficacy
has been shown to be dependent on dose and dose fre-
quency [9, 10], and there is good tolerability. Neverthe-
less, as all these treatments are only partially effective,
there is a need for modified treatment regimens and the
development of novel therapies.
Optimising therapy – currently available 
disease-modifying treatments
■ Switching between immunomodulatory agents
Although changing immunomodulatory agent could of-
fer the physician another strategy for improving thera-
peutic outcome among patients whose treatment does
not appear to be optimal, there is no conclusive evidence
to date to support this approach. Despite observations
from individual clinicians, which suggest that changing
from one DMT to another may optimise therapy, data
from well-designed, controlled clinical trials are still
needed to validate this approach.
■ Intensive immunosuppression
Immunosuppressive agents such as mitoxantrone and,
to a lesser extent, cyclophosphamide and cladribine (on
MRI only) have shown short-term efficacy in active re-
lapsing-remitting (RR)MS and, to a lower level, in sec-
ondary progressive (SP)MS [11, 12].
In the Mitoxantrone in Multiple Sclerosis (MIMS)
study, 188 patients with worsening RRMS or SPMS re-
ceived placebo or intravenous mitoxantrone every 3
months for 2 years [12]. The mitoxantrone groups expe-
rienced significant benefits compared with the placebo
group in terms of change in Expanded Disability Status
Scale (EDSS) score, confirmed EDSS progression, and
proportion of relapse-free patients. However, it is im-
portant to note that the placebo group showed a very low
rate of progression compared with the placebo groups
Table 1 Available and evolving interventions for multiple sclerosis (MS)
Component of MS pathogenesis Available interventions Evolving interventions
Systemic Immune dysfunction IFN β, glatiramer acetate, Immunosuppression, natalizumab, CTLA4, sirolimus, FTY720, 
immunosuppression xaliproden, teriflunomide, mesopram, statins
Blood-brain barrier Increased permeability/dysfunction Steroids, IFN β (glatiramer acetate) Natalizumab, CCR1 antagonists, metalloprotease-inhibitors
immunosuppression
CNS Inflammation (IFN β) glatiramer acetate, Immunosuppression, new immunomodulators, APL, vaccination
immunosuppression
Demyelination Neuroprotectants
Axonal loss Neuroprotectants, AMPA-antagonists, Na+ channel blockers, 
xaliproden
Scar formation/gliosis
Remyelination/regeneration Growth factors, pre-oligos
Interventions in parentheses indicate doubt over efficacy at the respective component of pathogenesis
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; APL altered peptide ligand; CNS central nervous system; IFN interferon
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from studies of interferon (IFN) β, suggesting that the
MIMS population may be skewed towards patients with
less aggressive disease [12].
As the effects of cytostatic agents also seem to be best
in early aggressive disease with high inflammatory ac-
tivity, the decision to treat using these drugs should be
made as early as possible – something that physicians
may be reluctant to do. Long-term toxicity (cumulative
cardiotoxicity and the possibility that there may be rare
links to secondary malignancies) is also a concern in re-
lation to the use of mitoxantrone; however, studies of ex-
perimental autoimmune encephalitis (EAE) in animal
models suggest that antagonists such as dexrazoxane
may protect against the cardiotoxic effects and help to
widen the therapeutic window of this cytostatic agent
[13].
Experimental and clinical observations have indi-
cated that high-dose immunosuppression followed by
autologous stem cell transplantation (ASCT) can induce
remissions in patients with MS [14]. However,ASCT has
been associated with both short- and long-term toxicity,
and a mortality rate of 6–8 % in high-risk cases [14].
The European Group for Blood and Marrow Trans-
plantation (EBMT) has recently reported a comprehen-
sive analysis of 85 patients (61 % female) with various
forms of MS who were treated with ASCT [15]. The me-
dian age was 39 (20–58) years and the patients suffered
from advanced disease, with a median EDSS score of 6.5
(4.5–8.5). The median interval from diagnosis to trans-
plant was 7 (1–26) years and the median follow-up was
16 (3–59) months. At the last assessment, 69 % of pa-
tients were improved or stable, 11 % had unconfirmed
progression, and 20 % had progressed or died, mainly as
a result of the procedure. The proportion of patients
with confirmed progression-free survival was 72 % at 3
years. However, due to the heterogeneous nature of the
study population and the uncontrolled, non-blinded de-
sign of the study, these data are not conclusive.
Although ASCT is purely experimental at present, a
controlled study is in progress to compare mitoxantrone
with ASCT. It is hoped that the results will determine
whether this procedure can offer the physician an alter-
native to immunosuppressive, cytostatic agents.
■ Drug combinations
If we take into account the complex pathology of MS,
combination therapy seems to be a logical step forward.
There are several prerequisites when choosing combi-
nations of drugs: each drug should be at least partially
effective; there should be a synergistic or at least addi-
tive mode of action, but the drugs should not have addi-
tive or compound toxicities; and the overall regimen
should be convenient (this may involve simultaneous or
consecutive [phase-adapted] application).
Combination therapy could be considered in patients
not responding to monotherapy as expected. However,
determining whether a patient has ‘breakthrough dis-
ease’, and therefore treatment is not optimal, is prob-
lematic. Alternatively, combination therapy could be
used as the initial treatment among patients with rapid
disease progression or, in the future, among those with
negative prognostic indicators (clinical, MRI, genetic
measures).
Drug combinations already used in daily practice in-
clude the use of steroids in addition to ongoing DMTs
for the management of relapses. At the clinical trial
stage, IFN β is being investigated in combination with:
 Periodic methylprednisolone pulses in ‘break-
through disease’ [16, 17],
 Mild oral immunosuppressants (e. g. methotrexate
[18] or azathioprine [19]),
 Intensive immunosuppressants (e. g. cyclophos-
phamide [20]).
Future promising combinations include IFN β-1a plus,
ideally, an agent with a different mechanism of action
such as an antioxidant [21–23]. Nevertheless, although
combination therapy is theoretically an attractive ap-
proach to optimising treatment, it may be difficult to
evaluate according to the principles of evidence-based
medicine.
New agents with a more selective mode of action
■ Humanised monoclonal antibodies
Humanised monoclonal antibodies are among the novel
therapeutic agents designed to target specific molecules
at the immunological synapse. Those currently under
investigation include:
 Anti-VLA-4 (natalizumab, which targets α4β1 inte-
grin): Phase II positive, Phase III ongoing,
 CTLA4-Ig (BMS188667, structural homologue of
CD28): Phase II interrupted,
 Daclizumab (targets the α-subunit of the high-affin-
ity interleukin (IL)-2 receptor): Phase I/II,
 Alemtuzumab (targets the cell surface glycoprotein
CD52): Phase II/III ongoing,
 Anti-CD20 (rituximab): Phase I,
 Anti-CD40L/-CD154 (IDEC-131): Phase I,
 Anti-IL-12 (J695): Phase I/II.
The most advanced of these is the humanised α4 inte-
grin antagonist natalizumab. Within the vasculature, α4
integrin antagonists prevent the recruitment and traf-
ficking of α4-expressing leukocytes across vascular
endothelium and into the CNS, by blocking interactions
with the endothelial cell surface receptors, vascular cell
adhesion molecule (VCAM)-1 and mucosal adressin cell
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adhesion molecule (MAdCAM)-1, potentially amelio-
rating inflammation [24].
In a recent randomised, double-blind trial, patients
with RRMS or relapsing SPMS received intravenous na-
talizumab or placebo every 28 days for 6 months [24].
There were pronounced reductions in the mean number
of new enhancing lesions and relapse rate among pa-
tients receiving natalizumab compared with those re-
ceiving placebo. However, natalizumab showed limited
activity, with inflammation and relapses resuming 1 or 2
months after the treatment was stopped, suggesting that
continued dosing is required to maintain the beneficial
effect. Safety data are so far available only from Phase II
trials in MS and Crohn’s disease, and represent limited
exposure in terms of patient numbers and treatment du-
ration [24,25].However,two large Phase III clinical trials
are ongoing to investigate this and whether the continued
use of natalizumab,either in mono- or combination ther-
apy, is associated with a reduction in effect.
■ Inhibitors of intracellular activation, signalling
pathways and T-cell proliferation
Another potential therapeutic avenue involves the use of
inhibitors to block intracellular activation, signalling
pathways and T-cell proliferation.Although these agents
may not be as specific as monoclonal antibodies, they
have the potential to target particular pathways involved
in MS. Several novel drugs are in preclinical develop-
ment, including:
 Inhibitors of signalling protein kinases (targeting
several activation cascades)
– lymphocyte-specific cytoplasmic protein-tyrosine
kinase P56lck (Lck)
– zeta-associated protein (ZAP)-70
– protein kinase C theta
– mitogen-activated protein kinase
 Inhibitors of calcium release-activated Ca-channel,
 Nuclear factor of activated T-cells,
 Inhibitors of Janus protein tyrosine kinase (JAK 3),
 Antimetabolites
– inhibitors of pyrimidine biosynthesis – gem-
citabine, leflunomide and FK778
– inosine monophosphate dehydrogenase inhibitor
– VX-497.
■ New oral immunomodulators/suppressants
Several oral immunomodulators are in Phase II/III stud-
ies, some of which are reviewed below.
Teriflunomide is a de novo pyrimidine synthesis in-
hibitor with antiproliferative activity. It is the active
metabolite of leflunomide, which is used in the treat-
ment of rheumatoid arthritis. Evidence from studies of
EAE and, more recently, one Phase II clinical trial sug-
gest that teriflunomide acts as an immunomodulator in
MS [26].
CCI-779 is an ester of sirolimus that acts, in part, by
binding to an intracellular cytoplasmic protein, FKBP12
[27]. This CCI-779:FKBP12 complex then binds to a cell
cycle regulatory protein, mammalian target of ra-
pamycin (mTOR), inhibiting its activation and sup-
pressing cytokine (IL-2)-driven cell proliferation. By
blocking T-cell proliferation, CCI-779 has the potential
to suppress the immune responses believed to be key in
autoimmune diseases such as MS.Furthermore, through
its properties as a neuroimmunophilin ligand, CCI-779
may also have neuroprotective and/or neuroregenera-
tive activities.
FTY720 is the first of a new class of immunosuppres-
sants with a unique mode of action. Structurally similar
to natural sphingolipids, it inhibits T-cell recirculation
by activating sphingosine 1-phosphate G-protein-cou-
pled receptors which, in turn, leads to the increased se-
questering of T-cells into the lymph nodes. FTY720 has
no effect on T-cell activation or expansion at clinically
relevant doses. Moreover, the preventative and thera-
peutic effects of oral FTY720 monotherapy that have
been shown in various models of EAE [28] and its abil-
ity to penetrate the blood-brain barrier make it an at-
tractive candidate for use in the treatment of MS.
Xaliproden exhibits immunomodulating activity, in-
hibiting the synthesis of tumour necrosis factor-α and
other cytokines, and neurotrophic properties. Origi-
nally developed for use in the treatment of patients with
neurodegenerative diseases, it has been shown to abro-
gate EAE and protect against disruption of the blood-
brain barrier [29].
Statins are cholesterol-lowering drugs that also ap-
pear to have some anti-inflammatory effects. In vitro ex-
periments indicate that statins, such as simvastatin, lo-
vastatin and mevastatin, can act to decrease the
migration of activated T-cells, and also induce a T-
helper cell cytokine shift [30]. An initial open-label, sin-
gle-arm study of simvastatin therapy in 27 patients with
RRMS has shown significant benefits in terms of reduc-
tion in the number and volume of Gd-enhancing lesions
seen on MRI [31].
Other agents undergoing Phase II studies include:
chemokine receptor-1 antagonists [32] and mesopram –
a phosphodiesterase inhibitor [33].
■ Neuroprotective agents
Neurodegeneration may occur at any stage of the MS
disease process. Therefore, the need to protect the CNS
against demyelination and axonal degradation, in addi-
tion to addressing the inflammatory process at the ear-
liest stage possible, is apparent.
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Potential targets for novel neuroprotective agents
include the α-amino-3-hydroxy-5-methyl-4-isoxa-
zolepropionic acid (AMPA)/kainate-type glutamate re-
ceptors. AMPA/kainate-type receptors mediate the toxi-
city induced by glutamate. During inflammation in both
EAE and MS, lymphocytes, brain microglia and
macrophages release excessive amounts of glutamate,
which can then activate AMPA receptors (Fig. 1) [34].
This prolonged excitatory neurotransmission of gluta-
mate can lead to neuronal damage – glutamate excito-
toxicity.
AMPA/kainate receptor antagonists, for example ta-
lampanel and E2007, can ameliorate EAE in rodents,
preventing clinical relapses and reducing axonal dam-
age [35, 36]. These effects do not appear to be related to
immunomodulation or anti-inflammatory actions [34].
Phase I and II studies have already been conducted in
other neurological indications (e. g. stroke and
epilepsy), but with unconvincing efficacy. The rapid im-
plementation of Phase II/III studies in MS is feasible, al-
though there are methodological challenges to be over-
come before proof-of-concept studies can begin.
Riluzole is an inhibitor of glutamate transmission
that is thought to act via pre-synaptic calcium channel
blockade [37], and is currently used as a treatment for
amyotrophic lateral sclerosis. In recent studies of EAE in
animal models, riluzole appeared to reduce focal in-
flammation, demyelination and axonal disruption [38].
The results of a pilot study in 16 patients with primary
progressive MS did not show any benefits in terms of
disability; however, improvements were seen on some
MRI measures [39].
■ Inhibitors of metabolic toxicity
Anticonvulsant drugs such as phenytoin and lamotrig-
ine do appear to be at least partially effective in the treat-
ment of some forms of neuropathic pain [40]. These
drugs act primarily by reducing sodium conductance,in-
creasing post-synaptic γ-aminobutyric acid-mediated
inhibition and reducing pre-synaptic calcium entry. In
vivo damage of CNS myelin and axons can be induced by
peroxynitrite [41],and nitric oxide donors have shown to
reversibly block axonal conduction, particularly in de-
myelinated axons [42]. However, recent experiments
have suggested that sodium channel blockers and in-
hibitors of sodium/calcium exchange may protect axons
from nitric oxide-mediated damage [43].In EAE models,
phenytoin treatment helps to protect spinal cord axons
and preserves axonal function/conductance [44] but, as
yet, results from clinical trials in MS are not available.
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Fig. 1 Possible role of AMPA/kainate
receptors in demyelination and axonal
loss. From Steinman L (2000) Multiple
approaches to multiple sclerosis. Nat
Med 6:15–16 [34], and published with
permission from the Nature Publishing
Group. AMPA α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid; APC
antigen-presenting cell; MHC major his-
tocompatibility complex; PLP proteo-
lipid protein
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Other potential inhibitors of metabolic toxicity in MS
include antioxidants. Free radical generation by
macrophages has been implicated in the demyelination
and axonal degeneration that are seen in MS [45–47].
Antioxidants, such as alpha lipoic acid and tirilazade
mesylate, have shown promising results in animals with
EAE [48,49].However, trials of dietary antioxidants such
as vitamin E or selenium in patients with MS have,so far,
failed to show an effect, leading to suggestions that the
effectiveness of such treatments may be related to
whether or not they are able to permeate the blood-
brain barrier [50]. A combination of IFN β plus vitamin
B12 has been found to be effective in EAE [21], and the
use of antioxidants in combination with IFN β is being
investigated in a variety of indications [22, 23].
Conclusions
Although there is now a wealth of different clinical
approaches and DMTs (Table 1), establishing better
guidance for clinical decisions will be crucial for further
advances in the day-to-day management of patients
with MS. Promising directions include the use of clini-
cal, imaging, pharmacogenomic and transcriptomic
databases to develop prognostic profiles, which can be
readily accessed by neurologists and used as decision-
making tools in the initiation and optimisation of treat-
ment.
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